The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia

Dasatinib has shown superiority over imatinib in achieving molecular responses (MRs) in chronic phase chronic myeloid leukemia but with a different toxicity profile, which may impact its overall benefit. Reported toxicities include pleural effusions and pulmonary hypertension, and although the incid...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Blood Adv
Autores principales: Fox, Lucy C., Cummins, Katherine D., Costello, Ben, Yeung, David, Cleary, Rebecca, Forsyth, Cecily, Tatarczuch, Maciek, Burbury, Kate, Motorna, Olga, Shortt, Jake, Fleming, Shaun, McQuillan, Andrew, Schwarer, Anthony, Harrup, Rosemary, Holmes, Amy, Ratnasingam, Sumita, Chan, Kah-Lok, Hsu, Wei-Hsun, Ashraf, Asma, Putt, Faye, Grigg, Andrew
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Hematology 2017
Materias:
Myeloid Neoplasia
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5727806/
https://ncbi.nlm.nih.gov/pubmed/29296724
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2016003889
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares